<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>47(1)</volume><submitter>Moreno G</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes.&lt;h4>Design&lt;/h4>A secondary analysis derived from multicenter, observational study.&lt;h4>Setting&lt;/h4>Critical Care Units.&lt;h4>Patients&lt;/h4>Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain.&lt;h4>Interventions&lt;/h4>Corticosteroids vs. no corticosteroids.&lt;h4>Main variables of interest&lt;/h4>Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fin</pubmed_abstract><journal>Medicina intensiva</journal><pagination>23-33</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9579897</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.</pubmed_title><pmcid>PMC9579897</pmcid><pubmed_authors>Sancho Chinesta S</pubmed_authors><pubmed_authors>Vidal Cortes P</pubmed_authors><pubmed_authors>Bonell Goytisolo JM</pubmed_authors><pubmed_authors>Armestar F</pubmed_authors><pubmed_authors>Moreno G</pubmed_authors><pubmed_authors>Martin Serrano F</pubmed_authors><pubmed_authors>Sole-Violan J</pubmed_authors><pubmed_authors>Jorge Garcia R</pubmed_authors><pubmed_authors>Blasco Cortes M</pubmed_authors><pubmed_authors>Estella A</pubmed_authors><pubmed_authors>Nieto M</pubmed_authors><pubmed_authors>Sanchez Montori L</pubmed_authors><pubmed_authors>Rodriguez A</pubmed_authors><pubmed_authors>Vallverdu Perapoch I</pubmed_authors><pubmed_authors>Trefler S</pubmed_authors><pubmed_authors>Marin-Corral J</pubmed_authors><pubmed_authors>Ferrer R</pubmed_authors><pubmed_authors>Casamitjana Ortega AM</pubmed_authors><pubmed_authors>Hidalgo V</pubmed_authors><pubmed_authors>Gomez Alvarez J</pubmed_authors><pubmed_authors>on behalf COVID-19 SEMICYUC Working Group</pubmed_authors><pubmed_authors>Socias-Crespi L</pubmed_authors><pubmed_authors>Jimenez Herrera M</pubmed_authors><pubmed_authors>Marques Parra A</pubmed_authors><pubmed_authors>Murcia Paya J</pubmed_authors><pubmed_authors>Fraile Gutierrez V</pubmed_authors><pubmed_authors>Loza A</pubmed_authors><pubmed_authors>Ruiz-Botella M</pubmed_authors><pubmed_authors>Pozo Laderas JC</pubmed_authors><pubmed_authors>Bodi M</pubmed_authors><pubmed_authors>Forcelledo Espina L</pubmed_authors><pubmed_authors>deAlba-Aparicio M</pubmed_authors><pubmed_authors>Diaz E</pubmed_authors><pubmed_authors>Martin-Loeches I</pubmed_authors><pubmed_authors>Albaya-Moreno A</pubmed_authors></additional><is_claimable>false</is_claimable><name>A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.</name><description>&lt;h4>Objective&lt;/h4>To determine if the use of corticosteroids was associated with Intensive Care Unit (ICU) mortality among whole population and pre-specified clinical phenotypes.&lt;h4>Design&lt;/h4>A secondary analysis derived from multicenter, observational study.&lt;h4>Setting&lt;/h4>Critical Care Units.&lt;h4>Patients&lt;/h4>Adult critically ill patients with confirmed COVID-19 disease admitted to 63 ICUs in Spain.&lt;h4>Interventions&lt;/h4>Corticosteroids vs. no corticosteroids.&lt;h4>Main variables of interest&lt;/h4>Three phenotypes were derived by non-supervised clustering analysis from whole population and classified as (A: severe, B: critical and C: life-threatening). We performed a multivariate analysis after propensity optimal full matching (PS) for whole population and weighted Cox regression (HR) and Fin</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-28T05:51:04.321Z</modification><creation>2024-11-13T18:51:12.163Z</creation></dates><accession>S-EPMC9579897</accession><cross_references><pubmed>36272908</pubmed><doi>10.1016/j.medine.2021.10.016</doi></cross_references></HashMap>